Literature DB >> 12810187

Modeling asthma and COPD in animals: a pointless exercise?

Brendan J Canning1.   

Abstract

Animal modeling has been essential to the development of every drug used to treat asthma and chronic obstructive pulmonary disease (COPD). Determining the safety and efficacy of new therapeutics will also depend upon animal experimentation, and future targets for therapeutic intervention will probably be identified during careful experimentation using animals. Animal modeling of chronic diseases is made possible by the fact that the processes associated with the regulation of breathing, gas exchange, airway smooth-muscle contraction and relaxation, blood flow through the pulmonary and bronchial vasculature, inflammatory cell recruitment, mucus secretion, mucociliary clearance and airway surface liquid composition are highly conserved in mammals. This conservation is apparent at the whole-organ level and also at the level of the cell and the genome. The subtleties of how the airways and lungs are regulated and experimentally measured in different species make the more complex processes associated with asthma and COPD difficult to faithfully model or duplicate in mammals, particularly in mammals such as rodents that are only distantly related to humans.

Entities:  

Mesh:

Year:  2003        PMID: 12810187     DOI: 10.1016/s1471-4892(03)00045-6

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  11 in total

Review 1.  Usefulness and optimization of mouse models of allergic airway disease.

Authors:  Fred D Finkelman; Marsha Wills-Karp
Journal:  J Allergy Clin Immunol       Date:  2008-03       Impact factor: 10.793

Review 2.  Metabolomics approach in allergic and rheumatic diseases.

Authors:  Rossana Scrivo; Luca Casadei; Mariacristina Valerio; Roberta Priori; Guido Valesini; Cesare Manetti
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.806

3.  Organophosphorus pesticides decrease M2 muscarinic receptor function in guinea pig airway nerves via indirect mechanisms.

Authors:  Becky J Proskocil; Donald A Bruun; Charles M Thompson; Allison D Fryer; Pamela J Lein
Journal:  PLoS One       Date:  2010-05-10       Impact factor: 3.240

4.  Homology modeling and flex-ligand docking studies on the guinea pig beta(2) adrenoceptor: structural and experimental similarities/ differences with the human beta(2).

Authors:  Marvin A Soriano-Ursúa; José G Trujillo-Ferrara; José Correa-Basurto
Journal:  J Mol Model       Date:  2009-03-05       Impact factor: 1.810

Review 5.  Using guinea pigs in studies relevant to asthma and COPD.

Authors:  Brendan J Canning; Yangling Chou
Journal:  Pulm Pharmacol Ther       Date:  2008-02-02       Impact factor: 3.410

Review 6.  Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.

Authors:  Miriam Braunstein; Anthony J Hickey; Sean Ekins
Journal:  Pharm Res       Date:  2019-10-24       Impact factor: 4.200

Review 7.  Experimental animal models for COPD: a methodological review.

Authors:  Vahideh Ghorani; Mohammad Hossein Boskabady; Mohammad Reza Khazdair; Majid Kianmeher
Journal:  Tob Induc Dis       Date:  2017-05-02       Impact factor: 2.600

8.  Qingfei Xiaoyan Wan alleviates asthma through multi-target network regulation.

Authors:  Zhenying Zhao; Yingbo Miao; Pengwei Pan; Binfeng Cheng; Gang Bai; Hong Wu
Journal:  BMC Complement Altern Med       Date:  2013-08-06       Impact factor: 3.659

9.  Antigen sensitization influences organophosphorus pesticide-induced airway hyperreactivity.

Authors:  Becky J Proskocil; Donald A Bruun; Jesse K Lorton; Kirsten C Blensly; David B Jacoby; Pamela J Lein; Allison D Fryer
Journal:  Environ Health Perspect       Date:  2008-03       Impact factor: 9.031

10.  Susceptibility to Aspergillus Infections in Rats with Chronic Obstructive Pulmonary Disease via Deficiency Function of Alveolar Macrophages and Impaired Activation of TLR2.

Authors:  Yuting Wu; Hong Xu; Li Li; Weifeng Yuan; Deming Zhang; Wenjie Huang
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.